The second benefit is the ability of TRAIL to target cancer cells with specificity, allowing for induction of apoptosis by p53-independent mechanisms while avoiding toxicity to the host observed with TNF-α (Takeda et al, 2007). The gene discussed is TNFSF10; the disease is cancer.